Griffin Stephen D. 4

What Happened
Stephen D. Griffin, President & CEO and a director of Anika Therapeutics (ANIK), had equity awards vest on March 14, 2026. A total of 19,236 shares were issued on vesting (12,824 from RSUs and 6,412 from performance-based PSUs). To satisfy tax-withholding obligations, 5,944 shares were retained by the issuer at an effective withholding price of $14.20 per share (total value withheld ≈ $84,405). The remaining net shares issued to Griffin were 13,292. The Form 4 reports the RSU/PSU vesting and the share withholding (codes A = award, M = conversion/exercise of derivative, F = tax withholding).

Key Details

• Transaction date: March 14, 2026 (reported on Form 4 filed March 17, 2026).
• Shares issued on vesting: 12,824 (RSU installment) and 6,412 (PSU first vesting installment).
• Shares withheld for taxes: 5,944 @ $14.20 = $84,405 (reported as disposition for tax withholding).
• Net shares added to Griffin’s holdings from this vesting: 13,292 (19,236 issued − 5,944 withheld).
• Shares owned after the transaction: not specified in the provided excerpt; see the full Form 4 for total holdings.
• Notable footnotes: RSUs = contingent right to one share; PSUs and RSUs were granted on March 14, 2025 and vest in three equal annual installments starting March 14, 2026. The withholding was to satisfy tax liabilities on vested awards.
• Timeliness: Filing date is March 17, 2026 for a March 14, 2026 transaction; no late-filing flag indicated.

Context
This was a routine equity vesting event for previously granted RSUs and PSUs rather than an open-market buy or sale. The tax-withholding (share retention by the company) is common practice and reflects payment of tax obligations on the vested awards, not a discretionary sale by the insider. For investors, vesting confirms compensation dilution and insider exposure but does not necessarily signal buy/sell intent.